IMPORTANT ANNOUNCEMENT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Federal Securities Class Action Has Been F...
March 27 2015 - 9:00PM
Wolf Haldenstein Adler Freeman & Herz LLP announces that a
class action lawsuit has been commenced in the United States
District Court for the Southern District of California against
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD). The class period is from
February 26, 2015 through March 11, 2015, inclusive (the "Class
Period"). Wolf Haldenstein encourages all shareholders who suffered
losses on shares purchased within the class period to contact us
immediately at (800) 575-0735 or email classmember@whafh.com.
On February 26, 2015, ACADIA announced its 2014 fourth quarter
and year-end financial results and told investors that it "remained
on track to submit its New Drug Application (NDA) to the Federal
Drug Administration (FDA) in the first quarter of 2015." Shortly
thereafter, on March 11, 2015, ACADIA issued a press release
announcing a change in the timing of its planned NDA submission to
the FDA for its drug NUPLAZID from the first quarter of 2015 to the
second half of 2015. In a separate press release the same day,
ACADIA announced the retirement of the Company's Chief Executive
Officer and President, Uli Hacksell.
This news and resignation announcement shocked investors,
leading to a material decline in the price of ACADIA common stock.
On March 12, 2015, the shares of ACADIA closed at $34.82, a decline
of $7.94 per share, a precipitous drop of 22.8%.
Wolf Haldenstein has extensive experience in the prosecution of
securities class actions and derivative litigation in state and
federal trial and appellate courts across the country. The firm has
over 70 attorneys in various practice areas; and offices in New
York, Chicago and San Diego. The reputation and expertise of this
firm in shareholder and other class litigation has been repeatedly
recognized by the courts, which have appointed it to major
positions in complex securities multi-district and consolidated
litigation.
If you wish to discuss this action or have any questions
regarding your rights and interests in this case, please
immediately contact Wolf Haldenstein Adler Freeman & Herz LLP
by telephone at (800) 575-0735, via e-mail at
classmember@whafh.com, or visit our website at www.whafh.com. All
e-mail correspondence should make reference to the "ACADIA
investigation."
Attorney Advertising. Prior results do not guarantee or predict
a similar outcome.
CONTACT: Wolf Haldenstein Adler Freeman & Herz LLP
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024